What benefits has the use of aspirin and extended-release dipyridamole in stroke patients been shown to have in comparison to clopidogrel in the PRoFESS study?
The PRoFESS study conducted in 2008 showed that the use of aspirin and extended-release dipyridamole was more effective than clopidogrel in reducing the risk of recurrent strokes. The study found that patients taking aspirin and extended-release dipyridamole had a 20% lower risk of recurrent stroke than those taking clopidogrel alone. Furthermore, the study also found that the combination of aspirin and extended-release dipyridamole was more effective in reducing the risk of major vascular events, including stroke, myocardial infarction, and vascular death, than clopidogrel alone. In conclusion, the PRoFESS study showed that aspirin and extended-release dipyridamole was more effective than clopidogrel in reducing the risk of stroke and other major vascular events. 